Abstract
Introduction
Despite forming the mainstay of pharmacological treatment of anxiety
disorders, response rates to serotonergic-based treatments are often less than
robust. As such, physicians are increasingly looking towards novel drugs. For
pharmaceutical companies, the pressure to meet this need and maintain market
share is growing as the patent expiries of three major brands draws near.
Scope
*Analysis of key marketed brands and late-stage pipeline drugs.
*Anxiety disorders-specific drug sales volume and value forecasts to 2017 in
the US, Japan, and five major European markets.
*Identification of future market events that are expected to affect anxiety
disorders drug revenues.
*Analysis of patient potential, unmet needs and clinical trial design in
anxiety disorder.
Highlights
Atypical antipsychotics are expected to change the landscape of the future
anxiety disorders market, with Seroquel XR set to benefit from first-to-market
status upon approval in generalized anxiety disorder. Seroquel XR will be
positioned as a second/third-line treatment for patients who have failed to
respond to available antidepressants.
In view of the high co-morbidity between anxiety and depression, it remains in
the interests of antidepressant manufacturers to maximize the patient
potential of their products. However, with three key brands set to experience
patent expiration over the forecast period (20082017), competition within the
antidepressant drug classes will intensify.
The presence of neurokinin (NK) receptor antagonists and corticotrophin
releasing factor (CRF) antagonists in the anxiety disorders pipeline have
generated much interest among interviewed key opinion leaders. Datamonitor
regards NK receptor antagonists as holding the greatest promise in the
treatment of anxiety disorders.
Reasons to Purchase
*Understand the current anxiety disorder market dynamics and how they are
expected to evolve out to 2017.
*Benchmark key late-stage pipeline anxiety disorder compounds against the
current market leading brands.
*Understand unmet needs in the anxiety disorders market based on key opinion
leader comments.
| 
View Cart
